A fluoroscopic-delivered composite graft that combines autologous mesenchymal stem cells, platelet-rich plasma and demineralized bone matrix proved safe as a treatment for distal tibial fracture, based on a small randomized study in Israel. "Future applications of freshly isolated MSCs may include delivery with active signal molecules and transient or permanent genetic and functional modifications of the cells. This graft, in turn, may be applied preventively in cases where difficulties in fracture healing are foreseen," the study authors wrote.
Stem cell treatment for fractures is safe in small study
SmartBrief Job Listings for Health Care
|Chief Financial Officer||
B. E. Smith
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|